NOVANTA INC
Novanta designs, manufactures and markets core technology components and subsystems for medical and advanced industrial original equipment manufacturers (OEMs). Its products support applications in precision medicine, manufacturing, robotics, automation and surgery, and are sold primarily to OEMs that incorporate them into systems for end users. Novanta sells globally, mainly through its direct sales force, with distributors also serving some markets. Novanta has two segments. Automation Enabling Technologies offers laser beam steering and scanning solutions, laser sources, robotic and precision motion products, robotic end-of-arm tooling, and air bearing spindles. Medical Solutions offers medical insufflators, endoscopic pumps and disposables, imaging and RFID solutions, advanced motion control, light engines, and integrated operating room technologies. Novanta is headquartered in Bedford, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $NOVT in the last 7 days.
No SEC Form 4 filings for $NOVT in the last 30 days.
See all $NOVT insider activity →Novanta Inc. (NOVT) reported Q2 revenue of $265.8M, up 10.3% YoY, with net income nearly tripling and cash from operations quadrupling. Adjusted EBITDA rose 16.4% to $60.7M. The company acquired Riverpoint Medical, expanding its medical consumables business. Q3 guidance projects over 21% revenue growth. Hedge fund ownership increased, but short interest remains high at 14.58% of float.
Eight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.
Novanta (NOVT) reported quarterly revenue exceeding expectations and raised guidance, yet its stock has declined. The company is seen as 26% undervalued, with a fair value estimate of $194.50, driven by strong demand in robotics and medical devices. However, its high P/E ratio of 88.6x raises valuation concerns.
Recent NOVT coverage spans earnings, mergers & acquisitions and financial news.
Earnings beat and strong guidance may lift the stock, but high short interest and valuation concerns could limit upside.
Earnings beat but stock decline reflects market concerns over guidance.
Potential short-term price pressure as investors reassess growth expectations after a strong quarter.
Guidance and acquisition-driven medical consumables ramp are likely to drive near-term estimate revisions and positioning around 2026 margin trajectory.
The article frames a demand broadening story for Novanta, anchored on a 37% YoY bookings increase and an implied revenue-outlook raise.
AlphAI scores every news story that mentions NOVT with an AI model for sentiment and relevance, and aggregates insider trades from NOVANTA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Novanta Inc. (NOVT) reported Q2 revenue of $265.8M, up 10.3% YoY, with net income nearly tripling and cash from operations quadrupling. Adjusted EBITDA rose 16.4% to $60.7M. The company acquired Riverpoint Medical, expanding its medical consumables business. Q3 guidance projects over 21% revenue growth. Hedge fund ownership increased, but short interest remains high at 14.58% of float.
2 min readEight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.
3 min readNovanta (NOVT) reported quarterly revenue exceeding expectations and raised guidance, yet its stock has declined. The company is seen as 26% undervalued, with a fair value estimate of $194.50, driven by strong demand in robotics and medical devices. However, its high P/E ratio of 88.6x raises valuation concerns.
3 min readNovanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.
6 min readConestoga Capital Advisors’ Q2 2026 investor letter said small-cap leadership improved, citing Russell 2000 results and AI and semiconductors. The firm highlighted Novanta Inc. (NASDAQ:NOVT) as a performance contributor, noting Aug. 5 close at $153.12 and 37% YoY bookings growth. Conestoga said Novanta raised its revenue outlook due to improving demand across robotics, medical tech, semiconductors, and AI.
4 min readNovanta (NASDAQ: NOVT) reported Q2 CY2026 revenue of $265.8 million, up 10.3% year on year and 1.3% above estimates, according to the company. Non-GAAP EPS was $0.89, up from $0.76 and 7.2% above consensus. It guided next-quarter revenue to $302 million (midpoint) and expects full-year EPS to rise from $3.48 to $3.94, per sell-side forecasts.
4 min readNovanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.
6 min readNOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 milli
6 min readNovanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.
5 min readNOVANTA INC (NOVT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0001076930 0001076930 novt:SixPointFiveZeroPercentTangibleEquityUnitsMember 2026-07-22 2026-07-22 0001076930 us-gaap:CommonStockMember 2026-07-22 2026-07-22 0001076930 2026-07-22 2026-07-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
3 min read
